(0.28%) 5 114.49 points
(0.28%) 38 346 points
(0.36%) 15 985 points
(-1.11%) $82.92
(5.25%) $2.02
(0.35%) $2 355.40
(0.48%) $27.67
(4.54%) $963.95
(-0.26%) $0.932
(-0.41%) $10.98
(-0.58%) $0.796
(1.67%) $93.40
4.89% $ 8.47
@ $11.31
Wydano: 14 vas. 2024 @ 21:07
Zwrot: -25.15%
Poprzedni sygnał: vas. 13 - 20:45
Poprzedni sygnał:
Zwrot: -1.65 %
Live Chart Being Loaded With Signals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 178 964 |
Średni wolumen | 570 877 |
Kapitalizacja rynkowa | 570.73M |
EPS | $0 ( 2024-03-21 ) |
Następna data zysków | ( $-0.440 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.32 |
ATR14 | $0.0150 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Chacko Jacob | Sell | 40 000 | Common Stock |
2024-02-06 | Chacko Jacob | Sell | 13 958 | Common Stock |
2024-02-07 | Chacko Jacob | Sell | 26 042 | Common Stock |
2024-01-02 | Multani Pratik S | Buy | 180 000 | Stock Option (right to buy) |
2024-01-02 | Multani Pratik S | Buy | 30 000 | Restricted Stock Unit |
INSIDER POWER |
---|
54.58 |
Last 99 transactions |
Buy: 6 373 472 | Sell: 3 807 004 |
Wolumen Korelacja
Oric Pharmaceuticals Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oric Pharmaceuticals Inc Korelacja - Waluta/Towar
Oric Pharmaceuticals Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-1.03M (0.00 %) |
EPS: | $-1.960 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-1.03M (0.00 %) |
EPS: | $-1.960 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-966 000 (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.07 |
Financial Reports:
No articles found.
Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej